Mycophenolate and methotrexate are better tolerated than azathioprine in myasthenia gravis
Neuromuscular Disorders · 2024
DOI: 10.1016/j.nmd.2024.03.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuromuscular Disorders, 2024. Verfasst von Katherine C Dodd und 10 weiteren Autor:innen. Beteiligte Einrichtung: Manchester Centre for Clinical Neuroscience, Northern Care Alliance NHS Foundation Trust, Salford Royal, Stott Lane, Salford, M6 8HD, UK; The Univers…. Hauptthemen laut MEDLINE: Myasthenia Gravis, Methotrexate, Mycophenolic Acid, Azathioprine. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Azathioprine is recommended as the first-line steroid-sparing immunosuppressive agent for myasthenia gravis. Mycophenolate and methotrexate are often considered as second-line choices despite widespread consensus on their efficacy. We aimed to gather real-world data comparing the tolerability and reasons for discontinuation for these agents, by performing a national United Kingdom survey of side effects and reasons for discontinuation of immunosuppressants in myasthenia gravis. Of 235 patients, 166 had taken azathioprine, 102 mycophenolate, and 40 methotrexate. The most common side effects for each agent were liver dysfunction for azathioprine (23 %), diarrhoea for mycophenolate (14 %), and fatigue for methotrexate (18 %). Women were generally more likely to experience side effects of immunosuppressants. Azathioprine was significantly more likely to be discontinued than mycophenolate and methotrexate due to side effects. There was no significant difference in treatment cessation due to lack of efficacy. This study highlights the significant side-effect burden of treatment for myasthenia gravis. Mechanisms to reduce azathioprine toxicity should be utilised, however mycophenolate and methotrexate appear to be good treatment choices if teratogenicity is not a concern. Women are disadvantaged due to higher frequency of side effects and considerations around pregnancy and breastfeeding. Treatments with improved tolerability are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Manchester Centre for Clinical Neuroscience, Northern Care Alliance NHS Foundation Trust, Salford Royal, Stott Lane, Salford, M6 8HD, UK; The University of Manchester, Manchester Academic Health Science Centre, Core Tec…
- The Walton Centre NHS Foundation Trust, Lower Lane, Liverpool, L9 7LJ, UK.
- Nottingham University Hospitals NHS Foundation Trust, Queen's Medical Centre, Derby Road, Nottingham, NG7 2UH, UK.
- University Hospitals Birmingham, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, B15 2WB, UK; Institute of Immunology and Immunotherapy, University of Birmingham, B15 2TT, UK.
- Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headley Way, Oxford, OX3 9DU, UK.
- Department of Neurology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, NE1 4LP, UK.
Zitieren
APA
Dodd, K. C., Ahmed, R., Ambrose, P., Holt, J. K., Jacob, S., Leite, M. I., Miller, J. A., San, P. P., Spillane, J., Viegas, S., & Sussman, J. (2024). Mycophenolate and methotrexate are better tolerated than azathioprine in myasthenia gravis. Neuromuscular Disorders. https://doi.org/10.1016/j.nmd.2024.03.010
Vancouver
Dodd KC, Ahmed R, Ambrose P, Holt JK, Jacob S, Leite MI, et al. Mycophenolate and methotrexate are better tolerated than azathioprine in myasthenia gravis. Neuromuscular Disorders. 2024. doi:10.1016/j.nmd.2024.03.010
BibTeX
@article{Dodd2024,
author = {Dodd, Katherine C and Ahmed, Rohan and Ambrose, Philip and Holt, James Kl and Jacob, Saiju and Leite, M Isabel and Miller, James Al and San, Pyae Phyo and Spillane, Jennifer and Viegas, Stuart and Sussman, Jon},
title = {Mycophenolate and methotrexate are better tolerated than azathioprine in myasthenia gravis},
journal = {Neuromuscular Disorders},
year = {2024},
doi = {10.1016/j.nmd.2024.03.010}
}
EUVIMED